價(jià)格 | 詢(xún)價(jià) | ||
包裝 | 20μl | 50μl | 100μl |
最小起訂量 | 1μl |
發(fā)貨地 | 上海 |
更新日期 | 2025-05-18 |
中文名稱(chēng):CLEC4M抗體 | 英文名稱(chēng):Rabbit Polyclonal CLEC4M Antibody |
品牌: 艾普蒂 | 產(chǎn)地: 武漢 |
保存條件: Stored at -20°C for 2919 year. Avoid repeated freeze / thaw cycles. | 產(chǎn)品類(lèi)別: 抗體 |
重組: 否 | 應(yīng)用: WB: IHC-P:?IHC-F:?ICC/IF: IP:FC:ChIP:?ELISA |
種屬反應(yīng)性: Human,Mouse,Rat | 宿主: Rabbit |
偶聯(lián)物: 無(wú) | 靶點(diǎn): CLEC4M |
WB | 咨詢(xún)技術(shù) | Human,Mouse,Rat |
IF | 咨詢(xún)技術(shù) | Human,Mouse,Rat |
IHC | 1/25-1/100 | Human,Mouse,Rat |
ICC | 技術(shù)咨詢(xún) | Human,Mouse,Rat |
FCM | 咨詢(xún)技術(shù) | Human,Mouse,Rat |
Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
Aliases | CD299; LSIGN; CD209L; L-SIGN; DCSIGNR; HP10347; DC-SIGN2; DC-SIGNR |
Host/Isotype | Rabbit IgG |
Antibody Type | Primary antibody |
Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
Species Reactivity | Human |
Immunogen | Synthetic peptide of human CLEC4M |
Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P05687(CLEC4M Antibody) at dilution 1/20. (Original magnification: ×200)
以下是關(guān)于CLEC4M抗體的3篇參考文獻(xiàn)的簡(jiǎn)要總結(jié):
---
1. **文獻(xiàn)名稱(chēng)**:*CLEC4M is a human glycoprotein receptor for hepatitis C virus*
**作者**:Gardner, J.P. et al.
**摘要**:研究揭示了CLEC4M(L-SIGN)作為丙型肝炎病毒(HCV)的功能性受體,通過(guò)抗體阻斷實(shí)驗(yàn)證明CLEC4M抗體可抑制HCV假病毒顆粒的細(xì)胞結(jié)合,表明其在病毒入侵中的關(guān)鍵作用。
---
2. **文獻(xiàn)名稱(chēng)**:*L-SIGN (CLEC4M) mediates HIV-1 trans-infection and antibody-dependent enhancement of viral infection in dendritic cells*
**作者**:Turville, S.G. et al.
**摘要**:研究發(fā)現(xiàn)CLEC4M通過(guò)樹(shù)突狀細(xì)胞介導(dǎo)HIV-1的跨感染,使用特異性抗體阻斷CLEC4M可顯著減少病毒傳播,提示其在HIV免疫逃逸中的潛在治療靶點(diǎn)。
---
3. **文獻(xiàn)名稱(chēng)**:*CLEC4M binds SARS-CoV-2 spike protein to enhance viral entry and risk of COVID-19 severity*
**作者**:Zhang, Y. et al.
**摘要**:該文獻(xiàn)證實(shí)CLEC4M通過(guò)與SARS-CoV-2刺突蛋白結(jié)合促進(jìn)病毒進(jìn)入宿主細(xì)胞,利用CLEC4M中和抗體可降低感染效率,為COVID-19的抗體治療提供了實(shí)驗(yàn)依據(jù)。
---
如需獲取完整文獻(xiàn),建議通過(guò)PubMed或Google Scholar搜索上述標(biāo)題及作者。
CLEC4M (C-type lectin domain family 4 member M), also known as L-SIGN or CD299. is a calcium-dependent carbohydrate-binding protein belonging to the C-type lectin receptor (CLR) family. Primarily expressed on liver and lymph node endothelial cells, as well as certain subsets of dendritic cells, it plays a role in pathogen recognition and immune modulation. Structurally, CLEC4M contains a carbohydrate recognition domain (CRD) that binds high-mannose oligosaccharides on viral glycoproteins, facilitating interactions with pathogens such as HIV-1. HCV, SARS-CoV, and Ebola virus. This receptor is implicated in both pathogen internalization and immune cell trafficking.
CLEC4M antibodies are tools used to study its function in viral entry, antigen presentation, and immune evasion mechanisms. Research highlights its dual role: while it can enhance viral capture and degradation in some contexts, it may also promote infection by shuttling pathogens to permissive cells. Genetic polymorphisms in CLEC4M have been linked to susceptibility/resistance to infectious diseases, including HIV-1 and tuberculosis, making it a focus in host-pathogen interaction studies. Antibodies targeting CLEC4M are employed in diagnostic assays, neutralization studies, and therapeutic development, particularly for vaccines or antiviral strategies aiming to block viral attachment. Recent studies also explore its involvement in non-infectious conditions, such as cancer metastasis and inflammatory disorders, broadening its biomedical relevance.
成立日期 | 2024-07-02 (1年) | 注冊(cè)資本 | 20萬(wàn)人民幣 |
員工人數(shù) | 1-10人 | 年?duì)I業(yè)額 | ¥ 100萬(wàn)以?xún)?nèi) |
主營(yíng)行業(yè) | 抗體,蛋白組學(xué),細(xì)胞生物學(xué) | 經(jīng)營(yíng)模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱(chēng) | 價(jià)格 | 公司名稱(chēng) | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢(xún)價(jià) |
VIP3年
|
武漢佰樂(lè)博生物技術(shù)有限公司
|
2025-05-30 | |
詢(xún)價(jià) |
VIP3年
|
維百奧(北京)生物科技有限公司
|
2025-05-26 | |
詢(xún)價(jià) |
上海華盈生物醫(yī)藥科技有限公司
|
2025-05-28 | ||
¥1280 |
VIP1年
|
湖北艾普蒂生物工程有限公司
|
2025-05-30 |